Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Rheumatoid Arthritis prescription drugs market is increasing by more than 11 percent

Kalorama Information : 10 March, 2008  (Company News)
A new report published by Kalorama Information estimates that the market for prescription drugs to treat Rheumatoid Arthritis topped $12 billion in 2006 and will increase over 11 percent a year through 2011.
The report entitled ‘Worldwide Market for Rheumatoid Arthritis and Lupus Treatments’ predicts the growth will be driven by new immunosupressants and other biologics.

Autoimmune diseases are some of the most difficult conditions to treat, with Rheumatoid Arthritis topping the list. Worldwide, more than 39 million people suffer from RA and drug developers are scrambling to understand the underlying causes and find new treatments.

The rheumatoid arthritis treatment market, held back somewhat in recent years by generic competition and the withdrawal of Vioxx and Bextra, is rebounding due to the performance of biologic treatments.

The availability and increased use of biologic treatments such as Enebrel, Rituxan and Remicade, representing three-quarters of the Rheumatoid Arthritis market in 2006, has revived growth in the industry, offsetting declines for older non-steroidal anti-inflammatory drug (NSAID) treatments, which tend to have more generic competition. Sales of biologic treatments will grow 85 percent by 2011, according to Kalorama Information.

The most common biologic approaches to Rheumatoid Arthritis involve immunosupressant drugs that block three actors in the immune system: T-cells, chemical messengers, and white blood cells. There are also novel new therapies that activate suppresser cells, inhibiting the production of inflammation enzymes, suppressing the production of inflammation agents, and preventing the production of B-cell antibodies.

“Any drug market would suffer from having the world’s most well-known drug withdrawal, but biologics are changing the story,” says Bruce Carlson, publisher of Kalorama Information. “They’ve shown better results than the standard treatments and, in the near-term at least, they won’t have competition from generics. They will represent the lion’s share of growth in the market.”

Kalorama Information’s report Worldwide Market for Rheumatoid Arthritis and Lupus Treatments analyses the current and potential world market and opportunities for prescription drugs to treat RA and Lupus.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   Â© 2012 ProHealthServiceZone.com
Netgains Logo